Clinical Trial Update: Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy [Phase 2]

View source ↗

Summary

Phase 2 trial update for BVS857 in Spinal and Bulbar Muscular Atrophy (SMA): safety, tolerability, and efficacy data completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal and Bulbar Muscular Atrophy

Drugs mentioned

• BVS857

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spinal and Bulbar Muscular Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2017-08-11